Level C· Early human research exploring benefitsCase Report / SeriesEurope PMCOpen access

Magnetic resonance imaging may predict deep remission in patients with perianal fistulizing Crohn's disease

Thomassin L., Armengol-Debeir L., Charpentier C., Bridoux V., Koning E., Savoye G.

Case Report / Series with a reported sample of 7 on Autoimmune Research, published in World J Gastroenterol (2017) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Case Report / Series
Journal
World J Gastroenterol (2017)
Reported sample size
7
Source database
Europe PMC
PMID
28694669
PMCID
PMC5483503
DOI
10.3748/wjg.v23.i23.4285
Citations
22

Abstract (original English)

Aim To evaluate the imaging course of Crohn's disease (CD) patients with perianal fistulas on long-term maintenance anti-tumor necrosis factor (TNF)-α therapy and identify predictors of deep remission. Methods All patients with perianal CD treated with anti-TNF-α therapy at our tertiary care center were evaluated by magnetic resonance imaging (MRI) and clinical assessment. Two MR examinations were performed: at initiation of anti-TNF-α treatment and then at least 2 years after. Clinical assessment (remission, response and non-response) was based on Present's criteria. Rectoscopic patterns, MRI Van Assche score, and MRI fistula activity signs (T2 signal and contrast enhancement) were collected for the two MR examinations. Fistula healing was defined as the absence of T2 hyperintensity and contrast enhancement on MRI. Deep remission was defined as the association of both clinical remission, absence of anal canal ulcers and healing on MRI. Characteristics and imaging patterns of patients with and without deep remission were compared by univariate and multivariate analyses. Results Forty-nine consecutive patients (31 females and 18 males) were included. They ranged in age from 14-70 years (mean, 33 years). MRI and clinical assessment were performed after a mean period of exposure to anti-TNF-α therapy of 40 ± 3.7 mo. Clinical remission, response and non-response were observed in 53

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansRectal FistulaCrohn DiseaseTumor Necrosis Factor-alphaAlbuminsC-Reactive ProteinGastrointestinal AgentsAntibodies, MonoclonalMagnetic Resonance ImagingTreatment Outcome

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research